Men with breast cancer face high mortality rates

 

Nashville, TN, USA (October 22, 2019) — Men with breast cancer are more likely to die than their female counterparts, across all stages of disease, with the disparity persisting even when clinical characteristics, such as cancer types, treatment and access to care are considered, according to a study by Vanderbilt researchers published in JAMA Oncology.

The persistent disparity, derived from an analysis of data from the National Cancer Database, suggests a possible distinct cancer biology, less effective treatment or compliance issues, and perhaps unhealthy lifestyles among men may be responsible for the lower overall survival rates, said Xiao-Ou Shu, MD, PhD, MPH, the study’s senior author.

The five-year mortality rate for men was 19% higher than for women. Additional studies are needed to identify the causes, she said, but any such studies would likely require international consortia because male breast cancer is so rare, accounting for less than 1% of cases.

“It is so rare, it would be extremely difficult for any single institute to recruit a sufficient number of patients for research,” said Shu, associate director for Global Health and co-leader of the Cancer Epidemiology Research Program at Vanderbilt-Ingram Cancer Center.

The study used 11 years of registry data from Jan. 1, 2004, to Dec. 31, 2014, which included 1.8 million female patients but only 16,025 male patients.

About 85% of male breast cancer is ER-positive, a proportion that is higher than female breast cancer patients (75%).

“That is a cancer type where patients usually fare better because we have a hormonal treatment,” Shu said. “We have a lot of treatment options for that type of breast cancer. In theory, men should have better outcomes and have lower mortality as women do if the treatment is equally effective.

“The question is whether there are some other biological differences between ER-positive male breast and ER-positive female breast cancer. We don’t know,” Shu said.

Previous studies have shown that men may not be as compliant with hormonal treatments as women, Shu said. Other factors that may influence mortality rates among men could be lifestyle factors, such as smoking, alcohol consumption, physical inactivity and obesity.

Clinical characteristics and undertreatments were associated with 63% of the sex-related mortality disparity.

“The bottom line is that we need more studies specifically focused on male breast cancer,” Shu said.

 


Vanderbilt University Medical Center, 22.10.2019 (tB).

Schlagwörter: ,

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung